The NIH consortium on Enhancing Development of Genome-wide Association Methods (ENDGAME) was formed in 2006 to bring investigators together to develop and test innovative, informative, and cost-effective study designs and analytical strategies and tools to perform genome-wide association studies on complex diseases. All strategies and tools developed through the program will be made available to the scientific community. The ENDGAME Consortium is led by NHLBI , with additional leadership and participation from other NIH Institutes including NCI , NIEHS , NHGRI , and NIGMS . Ultimately, the long-term goal of the consortium is to develop genome-wide association methods that may be used to (1) identify genetic susceptibility factors to disease, and (2) develop new treatment strategies to increase therapeutic responsiveness and efficacy.
The mission of ENDGAME is to advance our understanding of the utility of genome-wide association in human health and disease.
ENDGAME is a highly interactive consortium that consists of 11 independently-funded research groups. Each group is focused on developing specific analytic and computational methods and strategies, using various phenotype (and some simulated) data.
All ENDGAME groups are expected to advance knowledge of the design and analysis of genome-wide association as individual groups, and collectively as a consortium. The goals of ENDGAME include: